• First Hong Kong trial site, Queen Mary Hospital, activated to begin patient enrolment
• Phase 1 trial to determine safety, tolerability and pharmacokinetic data of RC220 with doxorubicin
• Additional Hong Kong site, Prince of Wales Hospital, also approved and scheduled to open in coming weeks

Race Oncology Limited has announced the site activation of Queen Mary Hospital in Hong Kong, enabling the commencement of patient enrolment for its Phase 1 clinical trial of RC220 in combination with doxorubicin in advanced solid tumour patients. Screening of patients has begun at the Queen Mary Hospital, with the first Hong Kong patient expected to be treated this month. Additionally, the Prince of Wales Hospital (also in Hong Kong) has received both ethics approval and regulatory approval from the Hong Kong Department of Health during August, and site activation is scheduled to occur in the coming weeks, allowing for the commencement of patient recruitment at the second Hong Kong site. Trial progress in Australia is also on track, with two patients treated with RC220 at the Southside Cancer Care Centre (Miranda, NSW). So far, 12 patients have been evaluated for inclusion by trial investigators and the Race clinical team. Due to the additional risks from doxorubicin in patients with advanced disease, recruitment is proceeding cautiously, but is expected to accelerate as additional sites are opened in Hong Kong and South Korea, which is expected to significantly increase the pool of eligible patients. Race's Phase 1 solid tumour clinical trial is open-label and will be conducted across multiple sites in Australia, Hong Kong and South Korea. In Stage 1, escalating doses of RC220 will be administered to up to 33 patients alongside doxorubicin to evaluate safety, tolerability, pharmacokinetics, and to determine the maximum tolerated combined dose (MTCD) of RC220. The study will also assess the impact on various clinical biomarkers. Following interim data analysis, the optimal dosage of RC220 in combination with doxorubicin will be evaluated in an additional cohort of 20 patients during Stage 2 to further examine safety, tolerability, and preliminary indications of cardioprotective and anticancer efficacy.